Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

Journal of Urology

Volumn 167, Issue 1, 2002, Pages 364-367

  Saint, Fabien ^a   Patard, Jean J ^a   Maille, Pascale ^a   Soyeux, Pascale ^a   Hoznek, André ^a   Salomon, Laurent ^a   Abbou, Claude C ^a   Chopin, Dominique K ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Bladder; Bladder neoplasms; Eytokines; Interleukin 2; Mycobacterium bovis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HELPER CELL; HUMAN; MALE; PRIORITY JOURNAL; SUPERFICIAL CANCER;

EID: 0036135232     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65469-9     Document Type: Article

References (18)

1. Intracavity bacillus Calmette-Guérin in the treatment of superficial bladder tumors
2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study
3. Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guérin for carcinoma in situ of the bladder
4. Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression
5. Dissecting the immunological effects of bacillus Calmette-Guerin (BCG) in vitro: Evidence of a distinct BCG-activated killer (BAK) cells phenomenon
6. Induction of Th1 and Th2 associated cytokine mRNA in mouse bladder tumor MB49 and BCG immunotherapy
7. Urinary interleukins in patients receiving intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
8. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value
9. Urinary interleukin-8/creatinine level as predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients
10. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer
11. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder
12. Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer
13. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: Statistically weighted syndromes analysis
14. Detection of interleukin-2 in the urine of patients with superficial bladder tumor after treatment with intravesical BCG
15. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression
16. Interleukin-2 dependent activation of tumor specific cytotoxic T lymphocytes in vivo
17. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
18. Genetically regulated response to intravesical bacillus Calmette-Guerin immunotherapy of orthotopic murine bladder tumour